Astrotech Corporation — FY2023 Form 10-K
Period: Fiscal year ended June 30, 2023, compared with FY2022. The request metadata says “2021 Q4,” but the supplied filing is for FY2023, not 2021 Q4.
Business context
Astrotech commercializes its mass spectrometry platform through wholly owned subsidiaries: 1st Detect (security and explosives trace detection), AgLAB (hemp and cannabis distillation process analysis), and BreathTech (breath-based disease screening). ATI owns and licenses the platform technology. The company reported one operating segment.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $750 thousand | $869 thousand |
| Gross profit / margin | $306 thousand / 41% | $192 thousand / 22% |
| Operating expenses | $11.366 million | $8.787 million |
| Operating loss | $11.060 million | $8.595 million |
| Net loss | $9.642 million | $8.330 million |
| Net loss per share | $5.95 | $5.24 |
| Operating cash used | $7.625 million | $6.792 million |
| Investing cash used | $3.844 million | $596 thousand |
| Financing cash used | $776 thousand | $2.095 million |
Revenue consisted of TRACER 1000 system sales, consumables, and maintenance services; fewer new units sold drove the decline. Gross margin improved as recurring revenue represented a larger share. R&D expense more than doubled to $5.591 million, reflecting platform work, AgLAB development and trials, BreathTech sample-library work, staffing, and equipment and facility costs. SG&A decreased modestly to $5.775 million. Other income and expense, net, was income of $1.418 million, versus $265 thousand in FY2022, primarily reflecting higher investment income and lower interest expense.
At June 30, 2023, cash and cash equivalents were $14.208 million and short-term investments were $27.919 million, for combined cash and short-term investments of $42.127 million. Net working capital was approximately $42.1 million; current assets were $44.713 million and current liabilities $2.665 million. Management said available cash and investments were expected to fund operating expenses and capital expenditures for at least 12 months from issuance of the financial statements, while also stating that additional funding would be needed in connection with continuing operations. Operating cash burn increased year over year.
Total liabilities were $2.956 million, including $607 thousand of lease liabilities. The related-party notes payable to CEO and Chairman Thomas B. Pickens III were fully repaid in September 2022; no term note payable remained at fiscal year-end. The company reported an accumulated deficit of $225.354 million. It recorded no income tax benefit and maintained a full valuation allowance against deferred tax assets.
Material changes and developments
- Total assets declined to $47.675 million from $56.221 million, mainly as cash was used for operations, investments, R&D equipment, share repurchases, and the legal settlement. Property and equipment rose to $2.670 million from $1.098 million.
- AgLAB began its first AgLAB 1000-D2 production run in FY2023. Management reported field-trial average ending-weight yield improvement of 30%; commercial adoption and repeatable results remain to be established.
- 1st Detect accepted an order for 17 TRACER 1000 units for delivery during calendar 2023. As of June 30, the product was deployed at approximately 29 locations in 14 countries. TSA cargo detection testing remained ongoing and delayed; U.S. cargo sales depend on approval.
- BreathTech expanded its Cleveland Clinic study to additional infections and conditions. Its BreathTest-1000 remained under development, without completed clinical testing or established FDA classification or marketing authorization.
- The company effected a 1-for-30 reverse stock split in November 2022 to regain Nasdaq minimum-bid-price compliance. It adopted a stockholder rights plan, which was scheduled to expire December 20, 2023.
- The company repurchased 10,316 shares for approximately $119 thousand. Its $1 million repurchase program was terminated in June 2023. A $5.983 million at-the-market offering agreement was also terminated before any shares were sold.
- A Delaware stockholder action was settled and dismissed with prejudice; $290 thousand of plaintiff attorneys’ fees and expenses was paid in FY2023. The settlement was not an admission of liability.
Outlook, risks, and unusual items
The filing provides no quantified revenue or earnings guidance. Management’s strategy is to commercialize the three applications of its mass spectrometry platform, expand production and sales, and continue R&D. The stated runway is qualified by ongoing losses, operating cash use, and the company’s expectation that additional funding will be needed. Equity financing could dilute shareholders; debt or licensing arrangements could impose restrictions or require relinquishing rights.
Key risks include limited revenues and customer concentration (four customers comprised substantially all FY2023 revenue), continued losses, uncertain product-market adoption, long sales cycles, and dependence on regulatory approvals. TSA cargo approval is outstanding for U.S. TRACER sales; BreathTest-1000 requires applicable FDA authorization, and its pathway and timing are uncertain. AgLAB is exposed to evolving hemp and cannabis laws, including federal restrictions. Supply-chain constraints, component price inflation, dependence on single-source suppliers, competition, and international currency and trade risks could affect costs and sales. The company also identifies pandemic, geopolitical, cybersecurity, intellectual-property, and Nasdaq-listing risks.
The independent auditor issued an unqualified opinion on the consolidated financial statements. The auditor did not audit or opine on internal control over financial reporting; management concluded controls were effective as of June 30, 2023. The filing’s disclosure-controls section separately refers to effectiveness “as of June 30, 2022,” an apparent period inconsistency.
Important facts for investors to verify
- Confirm the filing period: the supplied document is the FY2023 Form 10-K, despite the request metadata stating 2021 Q4.
- Track cash burn, investment liquidity and composition, and the timing and terms of any future capital raise.
- Check whether the 17-unit TRACER 1000 order was delivered and paid for, and monitor progress and timing of TSA cargo approval.
- Validate AgLAB’s reported field-trial yield improvement with commercial customer results, sales, and repeat orders.
- Monitor BreathTest-1000 clinical evidence, FDA classification, and any clearance, approval, or EUA submission and outcome.
- Review customer concentration and the FY2023 decline in revenue alongside the higher R&D spending and widening net loss.
- Reconcile the disclosure-controls date inconsistency and confirm subsequent developments after the September 28, 2023 filing date.